19-334 - Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery
Status: openA PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
Treatment for Melanoma
Contact Us
If you have questions about this trial or are interested in participating, please contact Wendy Blount, director of clinical trials, at (251) 445-9834 or wlblount@health.southalabama.edu.
Description
This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
Sponsors
This trial is sponsored by SWOG.Principle Investigator
Providers Associated With This Trial
![Poosarla_T2]()
View ProfileTeja Poosarla, M.D.Medical Oncologist and HematologistAssistant Professor of Interdisciplinary Clinical Oncology
